ESC Premium Access

SGLT2 inhibitors: uncovering the mechanisms of cardiovascular risk reduction

Topic: Pathophysiology and Mechanisms
Supported by an unrestricted educational grant from AstraZeneca

Congress Session

About the speaker

Professor Subodh Verma

St. Michael's Hospital, Toronto (Canada)
20 presentations
0 follower

4 more presentations in this session

The hidden burden of heart failure

Speaker: Professor F. Ruschitzka (Zurich, CH)


The clinical impact of SGLT2 inhibitor cardiovascular outcomes trials

Speaker: Doctor M. Bonaca (Aurora, US)


Lighting the way to the future of heart failure management

Speaker: Doctor M. Kosiborod (Kansas City, US)


Questions and answers

Speaker: Professor F. Ruschitzka (Zurich, CH) Doctor M. Bonaca (Aurora, US) Professor S. Verma (Toronto, CA) Doctor M. Kosiborod (Kansas City, US)


Access the full session

Spotlight on the effects of SGLT2 inhibition in heart failure (EBAC accredited)

Speakers: Professor S. Verma, Professor F. Ruschitzka, Doctor M. Bonaca, Doctor M. Kosiborod, Professor F. Ruschitzka...

About the event



31 August - 4 September 2019

Sessions Presentations

Related content

ESC Premium Access

Acute myocardial infarction with cardiogenic shock: case presentation.

29 August 2021

ESC Premium Access

Triglycerides: the underestimated player.

27 August 2021

ESC Premium Access

Inflammatory targets in atherosclerosis.

27 August 2021

This platform is supported by

logo Novo Nordisk